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Strengths and limitations of this study
 ► A study strength is the rigorous methodology, in-
cluding the use of randomisation, an assessment by 
nurse and iCBT administered with a support from a 
web psychotherapist.
 ► We will use employer’s and national registers to ob-
tain information about primary and secondary out-
comes; we will therefore not rely on self- reports on 
sickness absence or medication use.
 ► This is a pragmatic randomised controlled trial and 
the control group is care- as- usual controls; there-
fore, the comparator treatment will comprise the 
form of usual care that control participants receive.
 ► Due to our inclusion and exclusion criteria, there is 
likely to be a need to conduct a further trial of the 
intervention with respect to more severe cases of 
depression.
AbStrACt
Introduction Depression is a highly prevalent condition 
with typical onset in early adulthood. Internet- delivered 
cognitive behavioural therapy (iCBT) is a promising 
cost- effective and more widely available alternative to 
face- to- face CBT. However, it is not known whether it 
can reduce sickness absence in employees showing 
depressive symptoms. The randomised controlled trial 
component of the DAQI (Depression and sickness absence 
in young adults: a quasi- experimental trial and web- based 
treatment intervention) project aims to investigate if 
iCBT is effective in reducing sickness absence compared 
with care as usual (CAU) among young employees with 
depressive symptoms in primary care provided in an 
occupational health setting.
Methods and analysis This study will use a randomised 
controlled single- centre service- based trial of an existing 
iCBT programme (Mental Hub iCBT for Depression) 
to evaluate whether or not this treatment can reduce 
the number of sickness absence days in public sector 
employees aged 18–34 years who present at the 
occupational health service with mild depressive 
symptoms (score  ≥ 9 on the Beck Depression Inventory- 
IA). Control participants will be offered CAU, with no 
constraints regarding the range of treatments. The active 
condition will consist of seven weekly modules of iCBT, 
with support from a web therapist. Primary outcome will 
be participants’ all- cause sickness absence as indicated 
in employer’s and national administrative records up to 6 
months from study entry. Secondary outcomes relating to 
long- term sickness absence (over 11 calendar days) for 
mental and musculoskeletal disorders and psychotropic 
medication use will be obtained from the Finnish Social 
Insurance Institution’s administrative records; and short 
sickness absence spells (up to 11 calendar days) will 
be extracted from employer’s records. Analyses will be 
conducted on an intention- to- treat basis.
Ethics and dissemination The Coordinating Ethics 
Committee of the Hospital District of Helsinki and Uusimaa 
has approved the study (HUS/974/2019). The results will 
be published in peer- reviewed scientific journals and in 
publications for lay audience.
trial registration number ISRCTN10877837
IntroduCtIon
Depression is the single largest contributor to 
non- fatal health loss worldwide,1 and it causes 
a vast burden on the quality of life, society, 
healthcare systems and the economy.2 Three 
quarters of all mental health problems are 
established by the age of 24, and for mood 
disorders the median age of onset is 30 years.3 
Work disability is one of the key adverse 
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outcomes of depression in young adults. Over the past 
few decades, the proportion of young adults receiving 
disability benefits has considerably increased across 
Western Europe4 with mental disorders being the leading 
cause.5–7 Across the 28 European Union countries, the 
total cost of mental ill health is more than €600 billion, 
equivalent to 4.1% of gross domestic product (GDP).8 In 
Finland, between 2005 and 2015, the number of newly 
awarded work disability pensions due to mental disor-
ders among people under 35 years increased by 30%.9 
These facts strongly indicate that interventions aimed 
at prevention or early treatment need to focus primarily 
on younger people.3 However, mental health conditions 
such as depression are widely untreated or the treatment 
is postponed or discontinued due to lack of resources, 
shortage of trained professionals, cost of services and 
stigma.10 11 This unmanaged situation calls for new modes 
of treatment, which are easily implemented, safe, scalable, 
easily accessible, convenient, affordable and avoid stigma. 
Internet- delivered treatments may be suitable especially 
for young adults, as these types of treatments are in line 
with their preference for self- reliance.12 In addition, as 
the uptake of psychological treatments in working popu-
lations is low,13 one way to address it could be the delivery 
of internet- based mental health interventions in occupa-
tional settings.14 Early treatment of depressive symptoms 
is important, as depression can significantly impair young 
adult’s quality of life, social functioning and attachment 
to the labour market.9
Cognitive behavioural therapy (CBT) is one of the most 
effective treatments for various mental health problems, 
and evidence- based clinical practice guidelines such as the 
National Institute for Health and Care Excellence guide-
lines recommend it as the first- line treatment for depres-
sion.15 Internet- delivered CBT (iCBT) includes the same 
components as face- to- face CBT, that is, psychoeducation, 
de- arousal, exposure and cognitive restructuring, but is 
administered via the internet.16 Content typically consists 
of series of lessons, assignments and supplementary mate-
rial .17 Meta- analyses suggest that iCBT is equally effective 
as face- to- face CBT.18 19 Internet- delivered interventions 
have generally been shown to be effective in improving 
depression,12 17 20–23 both for those with severe depressive 
symptoms24 and for those with mild and moderate depres-
sion,25 26 as well as in increasing employees’ psychological 
well- being,14 but there is also some conflicting evidence 
showing lack of efficacy, particularly in primary care27 and 
in workplace settings.28
However, less is known about the extent to which this 
type of treatment can reduce work disability, for example, 
by reducing sickness absence. A possible pathway between 
reduction in depressive symptoms and decreased sickness 
absence is that timely access to adequate treatment can 
cut waiting times spent on sick leave.29 Even though sick-
ness absence is also determined by many other factors 
other than symptom severity, such as poor general health 
and work stressors,30 in previous studies within- subject 
changes in the severity of depressive symptoms have been 
associated with within- subject improvement in sickness 
absenteeism.31
Moreover, the evidence for treatments targeted to 
employees with depressive symptoms is scarce.32 A reanal-
ysis of data from five Australian randomised controlled 
trials (RCTs) showed that iCBT was associated with 
reduced self- reported sickness absence days among 
adults with depression or generalised anxiety disorder.33 
In contrast, three recent studies indicated that there were 
no significant differences in sickness absence between 
those adults with depressive symptoms who were treated 
with iCBT and those receiving care as usual (CAU) in a 
primary care26 34 or in an occupational setting.35 However, 
in previous studies sickness absence was self- reported. 
More generally, in most RCTs, participants have been 
recruited through self- referral (advertisements) or via 
specialised iCBT clinics while fewer studies have been 
conducted in ordinary primary care settings.36 Together 
these issues limit the generalisability of the results and 
point to the need for rigorously conducted pragmatic 
RCTs. A pragmatic trial is a trial that is designed to 
evaluate the effectiveness of an intervention in real- life 
routine practice conditions; in other words, to test if the 
intervention works in real life. The aim of a pragmatic 
trial is to maximise the applicability and generalisability 
of the results.37 Previous studies have recommended 
the development and conduct of a pragmatic type of 
RCT as a robust test of the effectiveness of iCBT within 
routine clinical care20 38–40 and in non- specialised clinical 
settings.41 Furthermore, large- scale studies are warranted 
before wide- scale dissemination of iCBT programmes can 
be recommended.42 In order to address this knowledge 
gap, the RCT component of our DAQI (Depression and 
sickness absence in young adults: a quasi- experimental 
trial and web- based treatment intervention) study will test 
the effectiveness of an iCBT programme ‘Mental Hub for 
Depression’ compared with CAU in terms of reducing 
sickness absence among young (18–34 years old)43 
employees showing depressive symptoms, using a large 
sample in a routine occupational health setting.
We hypothesise that the Mental Hub for Depression 
iCBT plus CAU compared with CAU will decrease sickness 
absence in young employees with depressive symptoms.
MEthod And AnAlySIS
Setting and participants
This is a single- centre, two- arm randomised controlled, 
CONSORT- EHEALTH guidelines44 compliant service- 
based pragmatic trial. The study will be conducted within 
Occupational Health Helsinki through an existing Mental 
Hub iCBT programme (https://www. mielenterveystalo. 
fi/ en/ Pages/ default. aspx#) developed and offered by 
the HUS Helsinki University Hospital, the largest hospital 
district in Finland. The City of Helsinki is the largest 
employer in Finland, and its occupational healthcare 
provider Occupational Health Helsinki provides primary 
care services for all of the municipality’s circa 38 000 
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Figure 1 Study flowchart.
employees. In the Finnish healthcare system, the majority 
of employees seek medical help from their occupational 
health service (OHS) for any illness, including non- work- 
related. OHS is funded partly by employers and partly 
through tax- natured payments levied from all taxpayers. 
The use of services is free of charge for the employees at 
the point of delivery. Even if the study is conducted within 
the Occupational Health Helsinki, the study is separate 
from the healthcare provider–patient relationship; that 
is, the Principal Investigator and her research team are 
not responsible for the medical care of the participants.
The present study will be conducted in the Helsinki 
Health Study (https://www. helsinki. fi/ en/ research-
groups/ helsinki- health- study) setting using the City of 
Helsinki personnel register data. These register data 
include sociodemographic and occupational factors, and 
short- term all- cause sickness absence data (1–11 calendar 
days). These data have been linked to long- term (over 11 
calendar days) diagnosis- specific, ICD-10 sickness allow-
ances (Social Insurance Institution (SII)), disability retire-
ment, ICD-10 (Finnish Centre for Pensions), prescribed 
and reimbursed psychotropic medication (Anatomical 
Therapeutic Chemical Classification (ATC) obtained 
from SII) and all- cause mortality for censoring purposes 
(obtained from Statistics Finland). These linkages will be 
updated annually.
Figure 1 shows the participant flow through the trial 
following the CONSORT statement. The overview of the 
study procedures follow the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT)45 
(online supplementary file 1) and the intervention 
description follows the TIDierR guidelines.46
In the present study, the focus is on young employees. 
The occurrence of mental ill health and the patterns of 
sickness absence are different in different age groups. 
The transitions to independence are increasingly 
protracted especially in terms of permanent employment, 
which typically requires postsecondary educational qual-
ifications. The European Commission’s Eurostat defines 
young employees as those aged 15–34.43
Inclusion criteria
(1) Visiting a nurse at the Occupational Health Helsinki 
with a mental health concern; (2) being 18–34 years old 
at the time of recruitment; (3) continuously employed 
by the City of Helsinki for at least 6 months before 
recruitment and permanent contract or a minimum of 
6 months of fixed- term contract left; (4) score ≥9 on the 
Beck Depression Inventory- IA (BDI- IA).47 The BDI cutoff 
score was set relatively low in order to ensure sensitivity 
to work- related stress and burnout that have been shown 
to precede more severe depressive states in employee 
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populations.48 Moreover, in comparison studies, BDI- IA 
has shown lower total scores than the BDI- II.49
Exclusion criteria
(1) Current high risk for suicide; (2) psychiatric comor-
bidity: substance dependence, bipolar affective disorder, 
psychotic illness, obsessive compulsive disorder, person-
ality disorder; (3) not able to read Finnish, Swedish or 
English well (the intervention is only available in these 
languages). The first two will be assessed by the nurse 
using patient records and all available information. 
The third will be based on participants’ self- assessment. 
This is a pragmatic trial, a real- world evaluation of an 
existing iCBT programme. Therefore, we will impose no 
constraints on CAU participants’ use of the intervention 
and there is a possibility of potential crossover.27
recruitment
At Occupational Health Helsinki, nurse is the usual first 
point of call for employees who experience any mental 
health difficulties. During the first appointment, BDI- IA 
will be routinely completed. If a patient in the target age 
group (18–34 years) scores≥9, has been employed by the 
City of Helsinki at least for 6 months, has at least 6 months 
of contract left and does not meet any of the exclusion 
criteria, he or she will be deemed to be eligible for partic-
ipation in the trial. Next, the nurse will inform the patient 
about the study by providing them with general informa-
tion about the study including a participant information 
sheet and consent form. Patients will be informed that 
participation in the intervention is voluntary, informed 
consent will be sought, their data will be pseudonymised 
and they cannot be identified from any study publications. 
Participants will be invited to sign the informed consent 
form to indicate that they have read and understood 
the study information including being free to withdraw 
at any time and without experiencing any negative feed-
back from the study team or related personnel. The form 
also states that regardless of their participation, they will 
continue to receive the treatment considered most appro-
priate for their condition by their nurse or physician. 
In Occupational Health Helsinki, the procedure is that 
patients experiencing depressive symptoms will routinely 
be offered a second appointment. If he or she wishes, the 
potential participant can thus take the participant infor-
mation sheet home and decide on participation during 
the second visit. The fact that all patients, those patients 
who choose not to participate, as well as control group 
participants, will meet with OHS staff and receive their 
CAU significantly reduces any potential ethical risk. All 
nurses who participate in recruitment have been trained 
for their role in recruitment from one of the research 
team members who is pedagogically qualified and a 
trained OH nurse by prior profession with several years 
of work experience at the Occupational Health Helsinki. 
Recruitment will begin in October 2019 and will continue 
for 18 months or until the planned sample size is reached.
Patient and public involvement
Neither the patients nor the public was involved in the 
development of the research questions, selection of 
outcome measures, study design or study conduct.
Sample size calculation
The planned sample size is 580—calculated on the 
primary outcome of sickness absence days in 6 months 
follow- up. A power calculation with expected 8 days of 
sickness absence for each control group member during 
the follow- up, an incidence rate ratio (IRR) of 1.45 
(control vs treatment) and dispersion parameter of 0.41 
in negative binomial regression, a significance level of 5% 
and a power of 0.80 indicated that 290 participants per 
group are required. IRR of 1.45 for controls means that 
those in the intervention group will have 0.69 (1/1.45) 
times the sickness absence days compared with those 
in the control group. Thus, the sample size calculation 
was based on expected eight sickness absence days per a 
control group participant and 5.52 sickness absence days 
per a treatment group participant.
randomisation
Participants will be randomly assigned to parallel groups 
in 1:1 ratio. Randomisation will be handled by a comput-
erised random number generator administered by an 
independent statistician who is not involved in the study. 
The numbers corresponding to the treatment group 
(I=iCBT) and the control group (C=CAU), respectively, 
will be placed in sequentially numbered opaque sealed 
envelopes by a research assistant. The randomisation 
envelopes will be then manually assigned to all Occupa-
tional Health Helsinki nurses, who will in turn assign them 
to participants after the eligibility has been determined, 
trial discussed and written informed consent obtained. 
All researchers and nurses will be blind during the rando-
misation scheme; however, blinding for treatment alloca-
tion will not be possible as it will be clear to the referring 
nurse as well as the participant whether the participant 
has been allocated to iCBT treatment or the control arm. 
The allocation list will be stored in a password- protected 
file on the University of Helsinki server.
outcomes
The primary outcome is the cumulative length of sickness 
absence, measured as sickness absence days in current 
and new spells during study period. The measurement 
includes sickness absence days between the study entry 
and the end of the 6 months follow- up from the study 
entry. Even if at the first stage of the study the follow- up is 
only 6 months, the data allow for a longer follow- up to be 
conducted at a later stage, as register data will be updated 
annually. In the participant information sheet, it has been 
stated that register data will be collected from 2019 to 
2024, so the participants have consented to a possibility 
of a longer follow- up. The measurement will be based on 
the intention- to- treat (ITT) principle including sickness 
absence days for all study participants.
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Table 1 Outcome measurements
Outcome Aim Hypothesis Time of measurement Data sources
Primary outcome
Recorded all- cause sickness 
absence days
Objective data on work 
disability
Improvement occurred (ie, 
lower incidence rate and 
fewer absence days in the 
intervention group)
Up to 6 months from study 
entry—longer follow- ups 





Recorded sickness absence 
days for mental disorders 
(F30- F49) (over 11 days)
Objective data on 
mental health- related 
work disability
Improvement occurred (ie, 
lower incidence rate and 
fewer absence days in the 
intervention group)
Up to 6 months from study 
entry—longer follow- ups 
are possible as these are 
register data
SII’s records
Recorded sickness absence 
days for musculoskeletal 
disorders (M00- M99) (over 
11 days)
Objective data on 
musculoskeletal 
disorders- related work 
disability
Improvement occurred (ie, 
lower incidence rate and 
fewer absence days in the 
intervention group)
Up to 6 months from study 
entry—longer follow- ups 
are possible as these are 
register data
SII’s records
Recorded short- term 
sickness absence (1–11 
days)
Data on short- term 
work disability
Improvement occurred (ie, 
lower incidence rate in the 
intervention group)
Up to 6 months from—longer 
follow- ups are possible as 
these are register data
Employer’s records
Psychotropic prescriptions Diagnosed depression 
or other (mental) health 
difficulties
Improvement occurred (ie, 
lower incidence rate in the 
intervention group, less 
DDDs)
Up to 6 months from study 
entry—longer follow- ups 
are possible as these are 
register data
SII’s records
DDD, defined daily doseSII, Social Insurance Institution of Finland.
We will focus primarily on all- cause sickness absence but 
will additionally examine sickness absence separately for 
mental and musculoskeletal disorders as they commonly 
co- occur, and their co- morbidity is associated with a 
higher risk of work disability.50 51 By focusing on all- cause 
sickness absence, we can demonstrate the overall change 
in sickness absence. If sickness absence days decrease due 
to mental disorders, it is also important to confirm the 
change in the total absence days. Moreover, all- cause sick-
ness absence was selected as primary outcome because we 
have no diagnostic data on short sickness absence spells. 
Short sickness absence spells constitute a large bulk of 
total sickness absence; by excluding these, we would have 
excluded a large number of absence days. An earlier 
study in the present study setting showed that the risk for 
long sickness absence for mental disorders increased with 
an increasing number of short sickness absence spells and 
days.52
The secondary outcomes are: (1) the cumulative 
length of long- term sickness absence both for depres-
sive and anxiety disorders (F30- F48 diagnoses) from the 
SII’s register (over 11 calendar days); (2) the cumulative 
length of long- term sickness absence for any musculoskel-
etal disorder (M00–M99) from the SII’s register (over 11 
calendar days); (3) the cumulative length of short sick-
ness absence from employer’s records (up to 11 days) and 
(4) defined daily doses (DDDs) of prescribed anxiolytics, 
hypnotics and sedatives and antidepressant medication 
purchases (ATC classification codes: N05B, N05C, N06A 
with DDDs) from the SII register. Prescription data will be 
obtained from the Finnish National Prescription Register, 
which is a national pharmacy claims database kept by the 
SII. The measurements include sickness absence days and 
prescriptions between the study entry and the end of the 
6 months follow- up. Overview of the outcome measure-
ments is presented in table 1.
treatment
The intervention (iCBT) will use an established mental 
health portal, structured web- based intervention model, 
the Mental Hub. The portal brings patients and profes-
sionals together through iCBT, which is available for a 
number of mental disorders. Referred patients can access 
therapy independently anytime and from anywhere except 
during working hours, and their personal web therapist 
who is a clinical psychologist monitors their development 
and supports them. Compared with the internet- based 
self- help interventions, therapist guidance or support 
during iCBT has been shown to improve treatment effect 
and reduce dropout rates53 54 and to be important for 
longer- term maintenance of symptom improvement.17 
Adherence is monitored through full completion or by 
session or page completed. For example, patients who 
do not complete all seven sessions can still make substan-
tial improvement by completing some of the sessions. 
Outside this study setting, a physician referral is required 
to access this therapy.
The Mental Hub can be used on a laptop, PC, tablet or 
smartphone and can be accessed in Finnish, Swedish and 
English. Mental Hub for Depression is a seven- module 
(therapy session) online CBT- based intervention using 
media- rich interactive content. The patient will access 
the platform using online banking details or a mobile 
ID (these are the typical means of accessing most public 
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as well as many private online services in Finland). The 
sessions represent best practice principles used in CBT 
programmes for depression including behavioural acti-
vation, cognitive restructuring, problem solving, setting 
goals and challenging inner beliefs. The programme 
consists of similar treatment structures and methods as 
conventional standardised CBT programmes, which are 
commonly divided into steps or therapy sessions. Each 
module follows a structured format that can incorpo-
rate introductory quizzes, videos, informational textual 
content, interactive activities, as well as exercises in written 
and behavioural format, such as thought and behaviour 
recording, and summaries. Participants are expected to do 
their homework tasks prior to completing the next session. 
In addition, accounts from three fictional peer support 
persons, who are using iCBT and gaining mastery over 
their symptoms, are incorporated into the presentation 
of the material. Automatic messages of positive affirma-
tion are sent to participants when they complete sessions 
and to remind them to complete further tasks as well as 
to inform them about new resources. The web therapist 
will give written feedback about progress and exercises 
during the treatment, and is available to answer patients’ 
questions. Patients can contact their web therapist via the 
portal any time and the therapist will answer within seven 
working days. Strict confidentiality rules apply; the thera-
pist has a duty to notify the patient’s healthcare provider 
only if their patient displays suicidal ideation or tenden-
cies. The tasks and instruments that are completed during 
treatment will be saved in the portal and patients can also 
make notes and save them within the system.
The typical length of the treatment is 7 weeks, with 
one session completed per week. The expected time 
to complete each session is 60 min. After 3 months of 
completion, there is a follow- up booster session. The 
effectiveness of any of the Mental Hub iCBT programmes 
has not been evaluated before.
Care as usual
CAU is defined as the routine care that employees receive 
when they are presenting with depressive symptoms at 
the OHS. All participants in the intervention arm and in 
the control group will have access to usual care. In prac-
tice, CAU may vary between patients and it is likely to 
include pharmacological treatment, psychotherapy, sick-
ness certification, visits to OH physician, OH nurse, OH 
psychologist, referral to psychiatric nurse, ‘depression 
school’ (a Finnish self- help manual and associated group 
prevention and treatment programme that uses materials 
adapted from ‘Control your Depression’),55 peer support 
group, iCBT (physician referral required) or a combina-
tion of these. We will not interfere with CAU, which may 
cause some crossover. In an earlier pragmatic trial of a 
different programme, 19% of the CAU (control) group 
had used iCBT.27
Engagement and usage measures
The online system will collect descriptive data relating 
to engagement and use of the platform by service users. 
Every patient login, completed page and filled assignment 
or measurement is time- logged, as all are on- platform 
messages between the patient and the therapist. Engage-
ment can be described, for example, as the completion 
time, sessions per week, number of messages sent to ther-
apist and total actions performed during the course of 
the treatment.
Statistical analyses
Statistical analyses for the cumulative length of recorded 
all- cause sickness absence (the primary outcome) will be 
performed with statistical models suitable for count data, 
including, for example, Poisson, negative binomial, zero- 
inflated, hurdle or difference in differences models. The 
model selection will be based on the actual frequency 
distributions found in the data. Secondary outcomes with 
count data, namely recorded sickness absence days for 
mental (F30–F49) and musculoskeletal disorders (M00–
M99), short- term sickness absence and psychotropic 
prescriptions, will be similarly assessed. The key measure-
ment unit for psychotropic medication purchases is DDD. 
Stratified analyses can additionally be run separately for 
those with and without sickness absence spells during the 
intervention.
In subsidiary analyses, outcomes with a dichotomous 
measure, that is, measurements of incidence or recur-
rence of sickness absence or psychotropic medication 
purchases, can additionally be assessed with the most 
applicable advanced statistical methods such as Cox 
regression models, where the survival time is defined as 
the distance between the study entry date and the date of 
outcome occurrence or the end of the follow- up.
Data on register- based measurements will also be 
collected 6 months prior to recruitment.
We will use two- sided p values with alpha≤0.05 level of 
significance for all tests.
The analyses will be conducted as ITT analyses involving 
all randomised participants, all retained in the group to 
which they were allocated, regardless of adherence.
All statistical analyses will be conducted with R, SAS 9.4, 
Stata 16 or other advanced statistical software. Results will 
be reported following the CONSORT and TIDierR guide-
lines.44 56
data management and data protection
The EU General Data Protection Regulation, Finnish 
data protection laws and the data protection guidelines 
of the University of Helsinki are followed strictly while 
storing and processing the data.
Each permanent resident in Finland has a personal 
identification (ID) number common to all registers.57 
These IDs will be used to link the data sets on a University 
of Helsinki computer, but the ID numbers will be replaced 
by study IDs when the data are given to researchers. Data 
on accessing iCBT will be collected via Mental Hub soft-
ware and stored on the Mental Hub server. Information 
collected via Mental Hub will be coded with a participant 
ID number to allow matching with sickness absence and 
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psychotropic medication records. In the final data, partic-
ipants are distinguished only by an ID number created for 
this study. All linked data will be collected and stored via 
the University of Helsinki server. Any identifiable informa-
tion collected remains confidential. During data analysis, 
only non- identifiable data will be used. At study comple-
tion, non- identifiable data will be written to a password- 
protected database. Participants will be informed during 
the consent process at application that the research team 
plans to disseminate the trial results in peer- reviewed 
scientific publications and scientific and lay publications 
and presentations.
In this research, personal data is collected for scientific 
research purpose only, and it is not further processed in 
a manner that is incompatible with this purpose. The 
data are stored until 2030 and will be destroyed at the 
end of that year. All data files will be password- protected 
and can be accessed only by authorised members of the 
research team who will need to sign relevant confidenti-
ality agreements.
The consent form is accompanied by a participant 
information sheet describing the purpose of the study, 
explaining that participation is voluntary, and the data 
processing and storing procedures.
The authors are aware of the right of the respondents 
to know what data related to him or her the researchers 
have, and to receive a copy of all personal data related 
to him or her. As advised by the University of Helsinki 
guidelines, the authors will contact the Data Protection 
Group if they receive such requests to ensure the correct 
course of action.
The risks related to processing the data are related to 
the possible annulment of anonymisation, which could 
lead to social harm for the respondents in the form of 
uncontrolled and unwanted access to their personal 
information, including health issues, which are catego-
rised as sensitive information by the EU General Data 
Protection Regulation (GDPR). However, according 
to the GDPR, the use of this information for scientific 
purposes is permitted. Risk for the annulment is low 
because of secure data management. The risk of social 
harm produced by a possible data breach is also assessed 
as low by the authors.
EthICS And dISSEMInAtIon
The study will be conducted and reported following the 
CONSORT statement,58 the CONSORT extension for 
web- based interventions (CONSORT- EHEALTH)44 and 
the SPIRIT guidelines.45 The results will be published in 
peer- reviewed journals, lay publications and in confer-
ence and seminar presentations. We aim to publish our 
peer- reviewed papers in Open Access journals.
dISCuSSIon
This large- scale pragmatic RCT will evaluate the effec-
tiveness of iCBT as a treatment for depressive symptoms 
for reducing sickness absence among young Finnish 
employees in an OHS setting. Although the effectiveness 
of iCBT for treating depression is well established,18 20 23 
important knowledge gaps remain. To the best of our 
knowledge, this study will be the first iCBT RCT using 
register- based sickness absence as the primary outcome 
and one of the first large- scale pragmatic RCTs conducted 
in a health service setting in (younger) employees. The 
present study will make an important contribution to 
the evidence base about online treatments for depressive 
symptoms. The primary outcome measure is the cumula-
tive length of sickness absence. The secondary outcomes 
are self- certified short- term sickness absence, long- term 
sickness absence for mental and musculoskeletal disor-
ders and psychotropic medication use.
If successful, the study will have significant implica-
tions for the effects and feasibility of integrating iCBT 
into existing healthcare infrastructure and to increase 
the scalability of the healthcare system, improving the 
capacity to deliver evidence- based mental healthcare to 
more patients and reducing their sickness absence.
Strengths and limitations
The study has several strengths. First, we will employ a 
rigorous protocol including the BDI assessment by a 
nurse and iCBT administered with support from a web 
psychotherapist. Second, employer’s and national regis-
ters are used to obtain information about primary and 
secondary outcomes; we will not rely on self- reports on 
sickness absence or medication use and in terms of the 
data obtained from SII (long- term sickness absence and 
prescribed medication), and there is practically no loss 
of outcome data to follow- up. The use of an employee 
cohort and routinely collected sickness absence and medi-
cation data enables a sufficiently large and representative 
sample, and a better real- world generalisability. Third, 
the study population represents widely different occupa-
tional groups and both white- collar and blue- collar occu-
pations. Fourth, our sickness absence follow- up is long, 
6 months, and we will have an option for even extending 
the follow- up. We will therefore be able to pick up longer- 
term effects. Finally, we will test if iCBT is effective in 
routine clinical non- specialised setting.
However, the study has also some limitations. First, this 
is a pragmatic RCT and the control group is CAU controls; 
it is therefore not possible to control for the effects of 
usual care the control participants receive. Future studies 
should investigate the effectiveness of iCBT for reducing 
sickness absence in comparison with face- to- face CBT 
and active control groups. Second, participants in both 
the intervention and control group may take up other 
forms of treatment, but we will not be able to collect data 
on such treatments. Third, in iCBT trials there is often 
a risk for high dropout and attrition rates. However, 
earlier research indicates that even 50% attrition does 
not necessarily distort the results.59 Fourth, there may be 
variation between nurses in terms of the adherence to 
the randomisation procedure and picking up the cases 
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with depressive symptoms. Fifth, the effectiveness of the 
Mental Hub iCBT in reducing depressive symptoms has 
not been evaluated.
Sixth, simultaneously addressing work environment 
factors would be important when aiming to reduce sick-
ness absence. Unfortunately, in the present study we 
cannot implement workplace interventions such as work 
modifications. However, for all participants, that is, for 
both those in the intervention group and those receiving 
CAU, addressing the work environment such as recom-
mending and implementing work modifications can be 
done, should the employers and OHS so decide. We can 
expect that due to randomisation these interventions 
do not differ between the intervention and the control 
groups. In the present study, we are able to test what is the 
contribution of iCBT to reduction of sickness absence.
Finally, if the employee terminates his/her contract with 
the City of Helsinki some point during the follow- up, we 
will not be able to follow them up for total and short- term 
sickness absence but only for long- term sickness absence 
and psychotropic medication use. However, in the City of 
Helsinki, the turnover is typically low, on average about 
10% a year.
Despite these limitations, our study will provide novel 
evidence about the effects of iCBT to reduce sickness 
absence in young employees with depressive symptoms.
trial status
The trial was launched in October 2019.
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